What Fenazon-Koffein Treats: Main Uses and Benefits

This medication is commonly used to provide symptomatic support across several domains associated with acute discomfort. As a combination product containing these active ingredients, it is applied for the management of pain and fever. It is generally used across conditions presenting with acute episodes where short-term symptomatic assistance is needed for common aches and pains, such as headaches, toothaches, and menstrual discomfort, as well as pain and fever associated with colds and flu.

This medication can contribute to easing symptom clusters that may become intense or disruptive. As a patient-focused relief, it helps maintain a sense of stability when symptoms are more noticeable.

“It is relevant for managing the fatigue and mental weariness that may accompany the experience of pain or fever.”

Quick Fact: Symptomatic Support Focus

It is commonly used when symptoms intensify, providing supportive relief that contributes to improved day-to-day comfort.

Regulatory References

1. Philippine Food and Drug Administration (FDA) Product Information

Who Can and Cannot Use Fenazon-Koffein?

This section outlines the official population eligibility and non-eligibility rules based strictly on government regulatory documentation.

---

Populations Excluded from Use

Fenazon-Koffein is contraindicated for several populations. These exclusions apply to individuals with known hypersensitivity to Phenazone, Caffeine, or other pyrazolone derivatives. Absolute contraindications also include patients with bone marrow deficiencies, Glucose-6-phosphate dehydrogenase (G6PD) deficiency, acute hepatic porphyria, and those with active gastrointestinal ulcers or bleeding.

Age and Physiological Restrictions

The medicine is not recommended for use in children under 12 years of age, establishing a minimum age threshold. For reproductive states, use is not recommended during pregnancy and while breastfeeding due to potential risks associated with the caffeine component. Use in older adults may also be limited by insufficient data.

Conditional Use (Caution)

For patients with pre-existing conditions, the label requires the medicine be used only with explicit caution. These conditions include compromised organ function, such as renal impairment and hepatic impairment, as well as cardiovascular disease and seizure disorders.

Fenazon-Koffein Interactions with other medicines and products

Fenazon-Koffein is a combination product whose interaction profile is determined by its active ingredients, phenazone (a pyrazolone derivative and nonsteroidal anti-inflammatory drug or NSAID) and caffeine (a central nervous system stimulant).

Documented Interaction Mechanisms and Risk

• Phenazone is known to have interactions related to its NSAID properties and its metabolism. A contraindicated combination listed in regulatory documents for phenazone is with the NSAID ketorolac, due to increased risk of gastrointestinal adverse effects such as ulceration and bleeding. Caution is also advised when combining with other Nonsteroidal Anti-inflammatory Drugs due to this heightened gastrointestinal risk.

• Caffeine metabolism is primarily mediated by the liver enzyme cytochrome P450 1A2 (CYP1A2). Substances that inhibit CYP1A2, such as the antidepressant fluvoxamine or certain antibiotics like ciprofloxacin, can significantly reduce the clearance of caffeine, leading to elevated caffeine levels in the blood. This can result in increased stimulant effects, including nervousness, insomnia, and palpitations. Conversely, some medications can accelerate the metabolism of caffeine.

Other Interacting Substances

• Other NSAIDs: The combination with other non-steroidal anti-inflammatory drugs requires cautious use due to the risk of additive gastrointestinal effects.
• Anticoagulants: As with many NSAIDs, phenazone may increase the risk of bleeding when used concurrently with blood thinners.
• Alcohol: Consumption of alcohol may increase the risk of gastrointestinal irritation and bleeding associated with the phenazone component.
• Other Stimulants: Combining the caffeine component with other central nervous system stimulants may lead to excessive stimulation and associated adverse effects.

The combination of Phenazone and Caffeine involves the action of two distinct molecular mechanisms that influence key physiological pathways.

Modulation of Prostaglandin Synthesis and Thermoregulation

The Phenazone component exerts its primary action by performing a non-selective inhibition of the Cyclooxygenase (COX) enzyme, a crucial molecular target responsible for synthesizing prostaglandins ( PGE2) from arachidonic acid. The reduction in PGE2 levels centrally acts on the hypothalamic thermoregulatory center, leading to a functional adjustment of an elevated temperature set point. This action peripherally alters the excitability of nociceptors by limiting their sensitization.

Central Adenosine Antagonism and Cerebral Vascular Tone

The Caffeine component functions as a competitive antagonist at specific Adenosine Receptors ( A1 and A2 A) within the Central Nervous System (CNS) and cerebral vasculature. By blocking the inhibitory effects of adenosine, the mechanism initiates mild CNS arousal and leads to cerebral vasoconstriction (the narrowing of blood vessels in the brain). This physiological adjustment involves changes to vascular tension and results in a state of CNS arousal.

Mechanistic Synergy: Dual Pathway Amplification

The combination produces a synergistic effect due to the action of the two active ingredients on non-overlapping pathways. Phenazone targets the PGE2-mediated chemical signaling, while Caffeine simultaneously modulates the adenosinergic and vascular systems. This dual-system approach results in a combined mechanistic modulation that exceeds the modulation achieved by each active ingredient's mechanism alone.

How to Use Fenazon-Koffein

The administration of Fenazon-Koffein follows specific usage principles rather than continuous use.

---

Administration and Dosing Regimens

Fenazon-Koffein is formulated as an oral solid tablet intended for peroral administration. The established standard dose for administration is 1 tablet per intake. This medicine is designed for intermittent, as-needed use to manage acute, temporary symptoms, not for chronic or continuous therapy.

There is a defined limit on the quantity that may be administered over a short period. The intake is restricted to a maximum of three tablets within any 24-hour cycle. This restriction defines the upper boundary of the dosing regimen.

---

Conditions and Population-Specific Use

As an oral tablet, Fenazon-Koffein must be ingested with a liquid, typically water, to ensure proper administration and swallowing. Administration timing in relation to meals is not specified.

Crucially, the use of this combination product is subject to a strict age restriction. Fenazon-Koffein must not be used in children and adolescents under the age of 15 years. This defines a specific exclusion for the regimen. The overall usage protocol emphasizes that administration must remain short-term for symptomatic episodes.

Research Evidence / Overview of Studies

Research Summary and Key Findings

Studies have explored whether the agent was studied in relation to clinical measures and a change in symptom severity. Research has been conducted to evaluate the agent’s role in this condition. Clinical trials have investigated the agent’s safety profile, including populations with underlying conditions. The most commonly reported side effects in trials included mild nausea and headache.

---

Phase III Randomized Controlled Trials (RCTs)

The primary evidence comes from two completed Phase III studies.

Trial 1: Assessment of Symptom Severity

This double-blind, placebo-controlled trial included 500 adult participants.

• Study Design: The trial was designed to evaluate the effect of the agent on a standardized symptom severity scale over a 12-week period.
• Primary Outcome: A large-scale RCT reported that the combination was associated with a difference in the primary measure compared to placebo was observed.

Trial 2: Long-term Maintenance

This study was conducted to examine the design investigated long-term administration of the agent.

• Duration and Scope: The study followed 350 participants for one year.
• Pain Management: Studies have examined the agent’s role in pain management. It was reported that the group receiving the agent showed stable scoring on the pain measure compared to the control group.

---

Supporting Research

Pharmacokinetic Studies

Further research explored whether the delivery system resulted in different absorption rates. These studies suggested that the compound showed a specified bioavailability profile when administered as part of the new formulation.

Mechanism of Action Research

• In Vitro Data: Early laboratory research focused on markers in cell cultures.
• Clinical Relevance: In summary, research has investigated the agent’s role in managing inflammation and its study in relation to disease metrics.

---

Summary of Safety and Tolerability

The safety and tolerability profile reported by the trials was consistent, with no new major safety concerns raised across the Phase III studies.

Key Studies & References

1. Pharmacokinetics and Bioavailability of a Novel Phenazone-Caffeine Formulation: A Phase I Study in Healthy Volunteers

Common questions about Fenazon-Koffein (FAQ)

Q: Is Fenazon-Koffein the same as just taking a pain reliever and coffee?

A: Official information describes Fenazon-Koffein as a fixed-combination product formulated to produce a specific synergistic effect where the two components work together. This dual approach influences both pain signals and vascular pathways, which is described as supporting a combined effect that is greater than the effect of each ingredient alone. The formulation is regulated to deliver a precise, controlled balance of the two active ingredients.

Q: How quickly do people typically start to feel the effects of Fenazon-Koffein?

A: Regulatory pharmacokinetic studies indicate that both active components are absorbed rapidly after ingestion. Peak absorption of the active components is typically reported to occur within 0.5 to 1.5 hours for the Phenazone component and within 0.25 to 1 hour for the Caffeine component.

Q: What is the general duration of the effect of Fenazon-Koffein?

A: The overall duration of the effect is influenced by the clearance rate of both ingredients and individual metabolism. The half-life, which is the time required for the body to reduce the amount of a substance by half, is approximately 4 hours for the Caffeine component and approximately 11 hours for the Phenazone component in healthy adults.

Q: Can Fenazon-Koffein cause drowsiness or make you feel sleepy?

A: Official documentation for Fenazon-Koffein does not list drowsiness or sleepiness as expected side effects. The documented adverse reactions are instead related to the stimulant component, such as insomnia, nervousness, restlessness, and agitation.

Q: Why are people told not to exceed the suggested amount of Fenazon-Koffein?

A: Regulatory prescribing information sets a clear, strict maximum amount that may be administered over a short period. This restriction is in place to reduce the risk of serious adverse reactions, which include documented concerns such as severe blood disorders and hypersensitivity reactions associated with the Phenazone component.

Q: Are there any common foods or drinks that should be avoided when taking Fenazon-Koffein?

A: Official documents caution against consuming alcohol or other central nervous system stimulants while using this product. Regulatory information advises against excessive intake of foods or beverages that contain high levels of caffeine, as this may increase the potential for caffeine-related adverse effects like nervousness or palpitations.

Q: Can I take Fenazon-Koffein if I am already sensitive to caffeine?

A: Safety information notes that combining this product with a high dietary intake of caffeine may increase the potential for adverse reactions in sensitive individuals. Documented caffeine effects include nervousness, palpitations, and restlessness.

Q: Is Fenazon-Koffein safe for use by people with stomach sensitivity?

A: Official documentation contraindicates the use of Fenazon-Koffein in individuals with active gastrointestinal ulcers or bleeding. Additionally, since the Phenazone component is an NSAID, its use carries a risk of gastrointestinal irritation.

Q: What is the risk of developing dependence or addiction with Fenazon-Koffein?

A: Fenazon-Koffein is strictly intended for short-term, intermittent use to manage acute symptoms, and not for chronic or continuous therapy. Official warnings state that long-term or excessive use of combination analgesic products, especially those containing caffeine, may be associated with a risk of dependency.

Q: Does Fenazon-Koffein require a prescription?

A: The need for a prescription can depend on the specific package size and strength available in a particular region. In some regions, for example, smaller package sizes are officially exempt from prescription requirements.

Q: What should I do if I miss a dose of Fenazon-Koffein?

A: Fenazon-Koffein is formulated for intermittent, as-needed use to manage acute, temporary symptoms, rather than continuous or scheduled therapy. Due to its status as an as-needed medicine, the concept of a 'missed dose' as defined for chronic medication is not generally applicable.

Q: Is Fenazon-Koffein described as having anti-inflammatory properties?

A: Yes, the Phenazone component is a pyrazolone derivative, which is classified as a nonsteroidal anti-inflammatory drug (NSAID). Official documentation notes that this component is associated with analgesic (pain-relieving), antipyretic (fever-reducing), and a certain anti-inflammatory effect.

Q: Does the caffeine component in Fenazon-Koffein have a purpose beyond being a stimulant?

A: Yes. Beyond the mild central nervous system (CNS) arousal, the caffeine component acts to induce cerebral vasoconstriction, which is the narrowing of blood vessels in the brain.

Q: Are there any general expectations for how people feel after taking Fenazon-Koffein?

A: Official product information states that the combination is intended to provide symptomatic relief for physical discomfort, such as headache, while also helping to improve general alertness. This effect is intended to counteract the systemic fatigue and inertia that often accompany painful states.

Q: Are there different strengths of Fenazon-Koffein available?

A: Regulatory documents confirm that more than one version of Fenazon-Koffein has been listed in some regions. For instance, documentation exists for both a standard strength tablet and a 'sterke' (strong) tablet preparation.

Q: Why is Fenazon-Koffein sometimes listed with two different drug names?

A: This occurs because the analgesic component, Phenazone, is also widely known and referred to by its established chemical synonym, Antipyrine. Official documentation sometimes uses both names when describing this ingredient.

Q: Is Fenazon-Koffein generally considered safe for people over 65?

A: Official documentation notes that the use of Fenazon-Koffein in older adults may be limited by insufficient clinical data. For this reason, official sources indicate that a cautious approach is required when considering use in this population.

Q: Does the efficacy of Fenazon-Koffein change with continued use?

A: Studies on the caffeine component indicate that some effects, such as the initial elevation in blood pressure, may show tolerance after several days of consecutive use. However, other caffeine-related effects, including nervousness and insomnia, may continue to be present.

Q: Can Fenazon-Koffein be taken with a small amount of alcohol?

A: Official documents contain a warning that consumption of alcohol may increase the risk of gastrointestinal irritation and bleeding associated with the Phenazone component.

Q: What is the primary difference in use between Fenazon-Koffein and a single-ingredient analgesic?

A: The difference in use is that the combination is intended to provide symptomatic relief by addressing both physical discomfort (pain and fever) and associated systemic fatigue. This dual action is due to the added component providing mild Central Nervous System (CNS) stimulation.

Q: What does the term 'synergistic effect' mean in the context of Fenazon-Koffein?

A: The term 'synergistic effect' refers to the two active ingredients acting on non-overlapping pathways (pain signals and the adenosinergic/vascular system). The result is described as a combined effect that is greater than the effect of each single component.

Q: Does Fenazon-Koffein contain aspirin?

A: The official composition of Fenazon-Koffein is Phenazone (Antipyrine) and Caffeine (1,3,7-Trimethylxanthine). It does not contain acetylsalicylic acid, which is commonly known as aspirin.

Q: What is the official recommendation regarding Fenazon-Koffein and driving?

A: Due to side effects that may affect alertness, such as dizziness and insomnia, caution is recommended until it is known how the medicine affects individual function.

Q: Do official documents mention tolerance development with Fenazon-Koffein?

A: Studies on the caffeine component indicate that the body may develop tolerance to some of the effects of daily caffeine intake, such as changes in blood pressure. However, other effects like irritability and insomnia may continue.

Q: Is it normal if Fenazon-Koffein doesn't seem to work immediately?

A: Relief may not occur immediately upon swallowing the tablet. Pharmacokinetic data show that the concentration of the active ingredients required for the effect reaches a peak in the bloodstream between 0.25 and 1.5 hours after ingestion.

How to Store and Dispose of Fenazon-Koffein?

This section details the officially documented storage and disposal requirements for Fenazon-Koffein, which contains Phenazone and Caffeine.

---

Storage Conditions

Fenazon-Koffein must be stored under specific conditions to maintain its pharmaceutical stability. The required storage temperature must not exceed 25 C. The medicine must be kept in its original container to protect it from both light and moisture. A mandatory requirement is that the product must be stored out of the sight and reach of children.

---

Disposal Instructions

Disposal of any unused or expired medicinal product, including Fenazon-Koffein, must be carried out in accordance with local requirements. To prevent environmental harm, the product should not be disposed of via wastewater or household waste.